MicrosoftTeams-image (49)

This high-impact program delivered a retina market overview,
presentations and panel discussions with KOLs and industry executives.

OIS Thank You Speakers Retina 2 (1) (1)



Allergan plc (NYSE: AGN), an AbbVie Inc (NYSE: ABBV) company, is a bold, global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company’s R&D model, which defines our approach to developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the industry.

Aviceda Ophthalmics

Aviceda Ophthalmics is a biotech company focused on the next generation of glyco-immune therapeutics (GIT's) leveraging the Glyco-Code® technology platform to address inflammatory diseases of the innate immune system.

Disease driven by dysregulation of the innate immune-inflammatory response is frequently a result of the same chronically activated, non-resolving cellular and non-cellular innate immune pathways. By unraveling the universal functionality of the Glyco-Code® and accessing the corresponding glyco-immune checkpoints, Aviceda can address a wide range of ocular immune-inflammatory, degenerative, and fibrotic diseases with significant unmet medical needs.

At Aviceda Ophthalmics, we exploit a unique family of receptors found expressed on all innate immune cells and their associated glycobiological interactions to develop transformative medicines. Combining the power of our biology with our innovative cell-based high-throughput screening (HTS) platform and proprietary nanoparticle technology, we are able to modulate the innate immune response specifically and profoundly.

Aviceda Ophthalmics is developing a pipeline of GITs that are delivered via biodegradable nanoparticles and which safely and effectively target both cellular and humoral aspects of inflammatory processes in AMD; this work will lay the groundwork for future development of GITs targeting other immune-inflammatory conditions.

Aviceda Ophthalmics’ lead optimized candidate nanoparticle as an intravitreal formulation, AVD-104, is being developed to target various immune system responses that contribute to pathology associated with non-exudative (Dry) AMD. GITs are the only therapeutics platform that can target BOTH cellular and humoral (i.e, complement) aspects of innate immune response profoundly and specifically, which differentiates from previous strategies to attenuate immune responses in non-exudative (Dry) AMD that focused only on shutting down humoral components of the immune response.

EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company has developed 5 FDA-approved sustained-release treatments in ophthalmology. DEXYCU (dexamethasone intraocular suspension) 9% was approved by U.S. Food and Drug Administration (FDA) on February 9, 2018. YUTIQTM (fluocinolone acetonide intravitreal implant) 0.18 mg, was FDA approved on October 12, 2018. ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg, a micro-insert licensed to Alimera Sciences, is currently sold directly in the U.S. and several EU countries. Retisert® (fluocinolone acetonide intravitreal implant) 0.59 mg, an implant, is licensed to and sold by Bausch & Lomb. The Company’s pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases.


Ora is the world’s leading full-service ophthalmic CRO and product development firm with offices in the United States, the United Kingdom, Australia and Japan. Over the past 40 years, we have proudly helped our clients earn more than 45 product approvals. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market. Ora’s pre-clinical and clinical models, unique methodologies and global regulatory strategies have been refined and proven across thousands of global projects. We bring together the world’s most extensive and experienced team of ophthalmic experts and R&D professionals to maximize the value of new product initiatives.


Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.


REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy.



1:00 - 1:10 PM

Welcome and Opening Remarks

Presented By:
Firas M. Rahhal, MD, Partner / Partner & Executive - ExSight Ventures / Retina Vitreous Associates Medical Group

1:10 - 1:20 PM

Innovating for Unmet Needs with Novel Endpoints

Presented By:
Keith Lane, Executive Director and Therapeutic Area Head, Posterior Segment - Ora Clinical

1:20 - 2:15 PM

Retina Innovation Showcase

Adverum Biotechnologies | Aaron Osborne, MD, Chief Medical Officer
GenSight Biologics | Magali Taiel, MD, Chief Medical Officer
Aviceda Therapeutics | Mohamed Genead, MD, Chairman, CEO & Founder
IVERIC bio | Pravin Dugel, MD, EVP & Chief Strategy and Business Officer
jCyte | Paul Bresge, CEO
ONL Therapeutics | David Esposito, President & CEO

2:15 - 3:00 PM

Clinical Panel Discussion

Allen C. Ho, MD, Attending Surgeon and Director of Retina Research - Wills Eye Hospital
Peter Kaiser, MD, Professor of Ophthalmology - Cole Eye Institute
Christina Y Weng, MD, MBA, Associate Professor of Ophthalmology - Baylor College of Medicine
Marco Zarbin, MD, PhD, Professor & Chair, Institute of Ophthalmology & Visual Science - Rutgers Medical School

Moderated By:
John Pollack, MD, Partner - Illinois Retina Associates/Rush University Medical Center

3:00 - 3:45 PM

Industry Panel Discussion

Paul Hallen, VP & Global Head, Retina & Glaucoma - Alcon
Andrew Stewart, AVP, US Commercial Retina - Allergan
Jay Duker, MD, Chief Strategic Scientific Officer - EyePoint Pharmaceuticals
Ram Palanki, SVP, Commercial Strategy & Operations - REGENXBIO

Moderated By:
Firas M. Rahhal, MD, Partner / Partner & Executive - ExSight Ventures / Retina Vitreous Associates Medical Group

3:45 - 4:45 PM

Virtual Networking